



**HAL**  
open science

## In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice

B. Delatour, Maryvonne Guégan, Andreas Volk, Marc Dhenain

### ► To cite this version:

B. Delatour, Maryvonne Guégan, Andreas Volk, Marc Dhenain. In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. *Neurobiol Aging*, 2006, 27 (6), pp.835-47. 10.1016/j.neurobiolaging.2005.04.011 . hal-03236868

**HAL Id: hal-03236868**

**<https://cnrs.hal.science/hal-03236868>**

Submitted on 26 May 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

***In vivo* MRI and histological evaluation of brain atrophy  
in APP/PS1 transgenic mice**

Benoît Delatour <sup>a</sup>, Maryvonne Guégan <sup>a</sup>, Andreas Volk <sup>b</sup>, Marie-Noelle Castel-Barthe <sup>c</sup>, Jesus Benavides <sup>c</sup>, Hans Paul Juretschke <sup>d</sup>, Marc Dhenain <sup>b,\*</sup>

<sup>a</sup> Laboratoire NAMC, CNRS, UMR 8620, Bât 446, Université Paris Sud, 91405 Orsay, France.

<sup>b</sup> Curie Institute, U350 INSERM, Centre Universitaire. Laboratoire 112, 91405 Orsay Cedex, France.

<sup>c</sup> Aventis Pharma, Neurodegenerative Disease Group, Centre de Recherche de Paris, B.P. 14, 94400 Vitry sur Seine, France.

<sup>d</sup> Aventis Pharma Deutschland GmbH, MRI lab, Geb, H821, #119 D, 65926 Frankfurt / Main, Germany.

\*Corresponding Author:

Marc Dhenain

Curie Institute, U350 INSERM, Centre Universitaire. Laboratoire 112, 91405 Orsay Cedex, France

Tel: +33 1 69 86 31 64 / Fax: +33 1 69 07 53 27 / Email: [Marc.Dhenain@curie.u-psud.fr](mailto:Marc.Dhenain@curie.u-psud.fr)

**Abstract:**

Regional cerebral atrophy was evaluated in APP/PS1 mice harboring mutated transgenes linked to familial Alzheimer's disease, using complementary methods. *In vivo* high resolution MRI was selected for measurements of brain atrophy and associated cerebro spinal fluid dilation; histological analysis was performed to reveal localized atrophies and to evaluate amyloid burden.

Young APP/PS1 mice examined at a pre-amyloid stage (10 weeks) showed disruption in development (reduced intracranial and brain volumes). Comparison of young and old (24 months) mice, indicated that both APP/PS1 and control brains endure growth during adulthood. Aged APP/PS1 animals showed a moderate although significant global brain atrophy and a dilation of CSF space in posterior brain regions. The locus of this atrophy was identified in the midbrain area and not, as expected, at isocortical/hippocampal levels. Atrophy was also detected in fiber tracts. The severity of brain atrophy in old APP/PS1 mice was not correlated with the extent of cerebral amyloidosis. The relevance of current transgenic mouse models for the study of brain atrophy related to Alzheimer's disease is discussed.

**Keywords:**

Alzheimer's disease, APP, Amyloid Precursor protein, A $\beta$  peptide, Atrophy, Brain, MRI, PS1, Presenilin, Mouse, Animal model, Transgenesis, Midbrain, Fiber tracts, Morphometry, Hippocampus, Development

## Introduction

Neuropathological hallmarks of Alzheimer's disease (AD) are senile plaques and neurofibrillary tangles (NFT). These lesions are mostly distributed in isocortical and hippocampal brain areas. Senile plaques are extracellular deposits of amyloid- $\beta$  ( $A\beta$ ) peptides surrounded by dystrophic neurites while tangles are pathological filaments primarily located in neuronal cell bodies and made of hyperphosphorylated tau proteins [23].

At the macroscopic level, brains from AD patients are characterized by a severe atrophy leading to dilation of the ventricular system and a widening of cortical sulci [51]. However, atrophy in AD is not a homogeneous process and, in the early stages of the disease, it affects mainly medial temporal areas [40] including the hippocampal formation [26]. Atrophy of these regions has been repeatedly reported to correlate with local density of NFT [4,30]. Progression of neurofibrillary lesions across isocortical areas (according to Braak and Braak stages [6]) has also been described as a good predictor of medial temporal lobe atrophy [21,29]. These observations suggest that NFT accumulation is crucially involved in the atrophy process [4,30], at least in the medial temporal areas that are the first regions to display neurofibrillary alterations in the early stages of the disease [10].

A relationship, although low, has been described between amyloid load and atrophy of the temporal lobe [30]. This suggests that  $A\beta$  deposition *per se* is also involved in the atrophy process even if its role, in AD patients, is underscored by the predominant deleterious incidence of neurofibrillary lesions. In any case, because of the simultaneous occurrence of both amyloid and neurofibrillary alterations in humans, it remains difficult to decipher how each of these primary neuropathological lesions participates in the genesis of cerebral atrophy in AD patients.

Answering the question of the relationship between each AD lesion and brain atrophy could be facilitated using transgenic animal models mimicking specific AD-related neuropathological alterations (e.g. amyloid deposits without NFTs) and therefore being prone to develop brain atrophy associated with "isolated" microscopic lesions.

AD transgenic mouse models are based on the overexpression of human mutated genes ( $A\beta$  precursor protein (APP) and presenilin-1 (PS1)) associated with familial AD [20,52]. In the different lines that have been created up to now, no NFT nor significant neuronal loss could be detected (e.g. [47]) except in one recently developed APP/PS1 knock-in model with localized neuronal loss in CA1/2 [9]. On the contrary, these mice are characterized by a graded age-related cerebral amyloidosis, associated with detrimental effects on the behavioral phenotype [1]. This supports the assumption that  $A\beta$  is a core lesion that induces a sequence of pathogenic events, resulting in increased levels of cerebral alterations and promoting behavioral disturbances [18,44]. One might therefore suspect, in accordance with this "amyloid cascade hypothesis", that transgenic mice overexpressing mutated APP should develop brain atrophy as a consequence of  $A\beta$  accumulation. Highlighting a relationship between brain atrophy and amyloid load might also be useful to screen the macroscopic effects of drugs and immunotherapies aimed at reducing or preventing the amyloid deposition [15].

Several studies have been carried out to determine the occurrence of selective brain atrophies in one transgenic mouse line (PDAPP model) reproducing AD-like cerebral amyloidosis [14,17,38,55]. These investigations reported compelling evidence of atrophy of the hippocampus, fornix and corpus callosum. However, because of their early occurrence, these lesions might be viewed as being caused by a neurodevelopmental deficit rather than by age-related brain shrinkage induced by  $A\beta$  deposits. The lack of observations in other transgenic

lines than the PDAPP model also weakens the contention that brain amyloidosis is invariably accompanied by cerebral atrophy.

The aim of the present study was therefore to: 1) characterize the pattern of cerebral atrophy in a new transgenic line expressing both human mutant APP and PS1. These mice have been recently characterized at the neuropathological level [3,56,57] and constitute a more aggressive model of cerebral amyloidosis than single APP transgenic lines. 2) evaluate the relationship between cerebral atrophy and A $\beta$  deposition (amyloid load) in this new APP/PS1 line.

APP/PS1 mice were first studied at a young age (10 weeks), preceding cerebral amyloid deposition [3]. Analyses in these animals were aimed at detecting the possible occurrence of brain atrophies in the absence of constituted A $\beta$  plaques. Double transgenics were also studied at two years of age when they show high amyloid load with extended number of aggregated mature plaques in numerous brain areas [3]. For all analyses, age-matched PS1 (amyloid free) mice were used as controls.

Several approaches were taken to evaluate brain atrophies. First, brain volumes were estimated by *in vivo* magnetic resonance imaging (MRI). This method, also used in two previous studies [38,55], prevents tissue distortion associated with brain removal, fixation, and sectioning and is well suited for longitudinal studies. In the present study, global and regional cerebral atrophy were evaluated on *in vivo* MR images by directly measuring brain volume and also by evaluating cerebrospinal fluid (CSF) volumes in all ventricles and periencephalic areas [12,13]. The latter measurements were based on the fact that brain atrophy leads to an increase of CSF volume in the regions close to the atrophied tissue [13].

Brain atrophy was also studied, following brain extraction, by extrapolating global and regional morphological measurements from serial histological sections (see also [14,17,38]). These postmortem analyses were correlated with *in vivo* MRI measurements (see also [38]).

Finally, to better assess the relationship between brain atrophy and A $\beta$  deposition in old APP/PS1 mice, the amyloid load of each animal was neuropathologically assessed and correlated with MRI- and histology-based brain morphometry.

## 1. Material and methods

### 1.1. Transgenic mice

Double Thy1 APP751 SL (Swedish mutation KM670/671NL, London mutation V717I introduced in the human APP751 sequence) x HMG PS1 M146L transgenic mouse line was generated and established in accordance with standard procedures using CBA/C57Bl6 hybrids [3,41,56]. APP/PS-1 double-transgenic mice were generated by crossing PS1 homozygous mice with hemizygous APP transgenic mice. The PS1 mice had been back-crossed on a C57Bl6 background for more than six generations, whereas the APP mice were on a CBA (12.5%) C57Bl6 (87.5%) background.

In these double transgenic mice, the amyloid deposition starts at the age of 2.5 months [3,56,57]. As differences in the development of A $\beta$ -deposition in the brain of APP transgenic mice might depend on the sex of the animals, [7] the present study only focused on one gender (females).

APP/PS1 mice were compared with age-matched amyloid-free PS1 animals. Two age groups were evaluated: 10 week-old animals (8 APP/PS1 and 7 PS1 mice) and 24 month-old mice (7 APP/PS1 and 9 PS1). One of the aged APP/PS1 animal had abnormally large CSF volumes surrounding its brain which suggested a brain atrophy that was obviously much more pronounced than in any other APP/PS1 animal. Two aged PS1 animals had a brain tumor that was detected during *in vivo* MRI and finally diagnosed by histological examination. All three mice were discarded from statistical analyses.

## **1.2. MRI experiment**

Brain images (Fig. 1-A, B, C, G) were recorded on a 4.7 Tesla Bruker Biospec 47/30 system, equipped with a 12 cm diameter gradient system (200 mT/m). A surface coil (diameter = 30 mm), actively decoupled from the transmitting birdcage probe (Bruker GmbH) was used for signal acquisition. Animals were anesthetized by isoflurane (5% for induction, 1-2% for maintenance). Respiration rate was monitored to insure animal survival until the end of the experiment.

Three-dimensional fast spin-echo (RARE) images were recorded with an isotropic nominal resolution of 117.2  $\mu\text{m}$  (TR=2500 msec, TE=10 msec, weighted TE=75.4 msec, RARE factor=16, NA=1, field of view=3x1.5x1.5, matrix=256x128x128). A "flip-back" was applied to enhance the signal from CSF [12]. The sensitivity gradient resulting from surface coil acquisition was corrected by a phantom based method [2,12]. Images of a 2.5% agar and NaCl 0.09% phantom were recorded under the same conditions as the brain images. Time domain data were filtered by a sine-squared function to enhance signal to noise ratio. Then, the 3D matrix that yielded isointense images of the phantom was calculated and applied to brain images (code written under IDL 5.4, Research Systems Inc.).

## **1.3. Brain positioning and segmentation protocol**

### **1.3.1. Brain Positioning**

The MR brain images from the different mice were rotated to be positioned in similar orientation (code written under IDL 5.4). Three coronal, 3 sagittal and 3 horizontal sections regularly distributed over the 3D block of the brain image were visualized on a computer screen. First the brain was rotated around the antero-posterior and ventro-dorsal axis to suppress any rotation of the brain on the coronal and horizontal views. Then it was rotated

about the left-right axis until the basis of the brain, checked on a central sagittal slice, was lying flat on the horizontal plane.

### 1.3.2. Intracranial volume assessment

The brain and surrounding CSF were semi-automatically extracted from other head tissue, by an observer blind to the animal genotype, using AMIRA software (Mercury Computer Systems, Inc. TGS Unit, Villebon, France). First, a threshold was visually defined to automatically segment the brain and surrounding CSF from other brain tissues (label voxel and remove island tools). This threshold was easy to find thanks to the high contrast between intracranial structures (brain and CSF) and other tissue. Then, this initial segmentation was manually refined (drawing tools) on a slice by slice basis to make sure that the border between the intracranial structures and surrounding tissue was correctly localized. Borders were then smoothed (AMIRA smooth tool). The first and last slices corresponded respectively to the most anterior part of the frontal pole (including peri-encephalic CSF) and to the most posterior part of the occipital cortex (including peri-encephalic CSF). Brain sampling volume was therefore performed between +3.56 mm and -4.72 mm from Bregma according to standardized stereotaxic atlas [33]. The length of the antero-posterior axis of each brain was defined by counting the number of sections between these two slices and then by multiplying this number by 117.2  $\mu\text{m}$  (MRI slice thickness). An average of 77 coronal sections were outlined for each animal. The surface of each section and then the global volume, referred to as the intracranial volume ( $V_{\text{intC}}$ ), were evaluated (AMIRA tissue statistic tool).

### 1.3.3. Evaluation of CSF volumes

CSF volume was evaluated from the same MRI brain slices used to calculate the intracranial volume. The intensity threshold separating CSF pixels from other pixels was computed using the following method: The signal intensity (I) and its standard deviation (SD) were assessed in the amygdala. Pixels that displayed an intensity superior to  $I+4.41717*SD$  were considered

to be CSF (4.41717 corresponds to a 0.001 % confidence interval for a Gaussian population). CSF voxels were manually labeled and classified as belonging to various brain areas (see Fig. 1-A, B, C, G) by using a freeware (Display available at <ftp.bic.mni.mcgill.ca>) that allowed the control of voxel labeling in the three directions. The brain areas were defined, as follows, on the basis of a mouse brain atlas [33]. First the brain was divided into its anterior and posterior parts, separated by the first slice displaying the interpeduncular fossa. **CSF in the anterior part of the brain** was classified into 1) CSF in the part of the lateral ventricle located posterior to the interventricular foramen (CSF<sub>LV</sub>). This region of interest was selected because it is an area where the lateral ventricles surround the dorsal hippocampus. Its dilation might thus reflect hippocampal atrophy. 2) CSF in the third ventricle and in the part of the lateral ventricle anterior to the interventricular foramen (CSF<sub>3V</sub>). 3) CSF in the anterior periencephalic areas (CSF<sub>antC</sub>). **CSF in the posterior part of the brain** was classified into 1) CSF in the mammillary fossa (or interpeduncular fossa) (CSF<sub>mam</sub>). 2) CSF located around the midbrain (CSF<sub>midbrain</sub>). 3) CSF in the aqueduct of Sylvius (CSF<sub>sylv</sub>). 4) CSF in other posterior peri-encephalic areas (CSF<sub>postC</sub>). 5) Some voxels localized at the junction between the temporal and occipital areas were hyperintense because of susceptibility effects caused by the internal ears located just underneath this area. They were labeled as artifactual voxels. Their determination was made by a single user who was blind to the animal genotype.

Once images from all animals had been labeled, we double-checked that the voxel attribution to the different regions was consistent for all animals. Then, the number of voxels belonging to each region was automatically counted by the ‘Display’ freeware. We controlled that the number of inner ear-related artifactual voxels did not differ between the four animal groups ( $U_s > 9$ , ns).

A score of global brain atrophy was evaluated by summing up CSF volumes from all brain regions. To correct for inter-individual differences in skull size, the ratios between CSF

volumes and intracranial volumes were computed on both total and regional (anterior or posterior) raw CSF data. These corrected measures were termed as “indices”.

#### 1.3.4. Direct evaluation of brain volume and of midbrain height

A direct MRI-based evaluation of brain volume ( $V_{Br}$ ) was performed by removing the volume of CSF surrounding the brain from the intracranial volume:

$$V_{Br} = V_{intC} - (CSF_{antC} + CSF_{postC} + CSF_{mam} + CSF_{midbrain}) \quad \text{Eq. [1]}$$

To take into account differences in intracranial size, the ratio between  $V_{Br}$  and intracranial volume was calculated as a corrected measure of global brain atrophy (see also [38,55]).

Midbrain height was determined, on sagittal views of the brain, as the distance between the basis of the aqueduct of Sylvius and the roof of the mammillary fossa (Fig. 1-G).

### **1.4. Neuropathology**

Animals were rapidly decapitated after imaging and their brain was fixed in 10 % buffered formalin for 5-10 days. Brains were then stored overnight in a solution of 20% glycerin and 2% dimethylsulfoxide (DMSO-G) in 0.1 M phosphate buffer for cryoprotection. Brains were subsequently sectioned into 40  $\mu\text{m}$ -thick coronal sections on a freezing microtome. Sections ranged from the frontal pole to the end of the caudal part of the hippocampus. Obviously, the brain sampling volume used for histological material (approximately assessed from Bregma +3.20 mm to Bregma -4.04 mm according to Paxinos [33]) was smaller than that covered by the MRI measurement (see above).

One out of eight serial floating sections were rinsed with 0.1 M phosphate buffer and mounted on gelatine-coated glass slides before being processed for Nissl and Congo red staining. Nissl stain made use of thionin and labeling of amyloid deposits was done by standard Congo red

staining (30 min in a 80% ethanol solution saturated with congo red and sodium chloride; adapted from [36]). Each slice was then digitized using a Super CoolScan 8000 ED high-resolution scanner (Nikon, Champigny sur Marne, France).

#### 1.4.1. Evaluation of brain and hippocampal volumes

The brain volume and the volume of the hippocampi (including both Ammon's horn and the subicular complex) were assessed from Nissl and Congo red stained serial sections. The surface of the brain and the hippocampus was determined, after manual delineation on the histological sections, using the histogram function of Photoshop 6 (Adobe, Paris, France). Volumes were then estimated from serial surfaces according to an adapted Cavalieri method [39] and were normalized after calibration in Photoshop to be expressed in mm<sup>3</sup>. A correction of the hippocampal volume was calculated by dividing the hippocampal volume by the brain volume. Some brain sections from one 24-months old PS1 animal had been altered during histological processing and the brain and hippocampal volumes could not be precisely evaluated. Consequently, volumetric data (and also measurements of corpus callosum length; see below) from this animal were excluded from statistical analysis.

#### 1.4.2. Evaluation of atrophy in selected brain structures (fiber tracts, mammillary bodies and midbrain area)

All morphological measures (distances or surfaces), with the exception of the corpus callosum length, were performed, following manual delineation on digitized histological sections, with the measure tools of Photoshop 6.

The antero-posterior length of corpus callosum was determined as the distance between the most rostral and caudal slices where it could be identified. Corpus callosum thickness was evaluated at two antero-posterior levels as the distance between its most ventral and dorsal points. Rostral thickness was measured on the first frontal slice where the corpus callosum could be identified (corresponding approximately to +1 mm / Bregma according to [33]).

Caudal thickness was measured on the first slice where the dorsal hippocampus was present (corresponding approximately to -1 mm / Bregma according to [33]). The fornix diameter was measured at the same level as the caudal corpus callosum thickness. Brain sections were observed under darkfield illumination in order to facilitate fornix identification that, in some animals, was hardly possible using brightfield illumination conditions. Diameter of the mammillothalamic tract was measured at -1.5 mm / Bregma according to [33]. This anatomical level was easily identified in all studied mice.

The surface of the mammillary bodies was evaluated at a stereotaxic level close to -2.7 mm / Bregma [33]. At this level both lateral and medial mammillary nuclei as well as pre- and supra- mammillary nuclei were identified. For one 24-months old PS1 animal, clear delineation of the mammillary bodies at this stereotaxic level was impossible and therefore this mouse was not included in statistical analysis

The surface of the internal capsule was measured at the level of rostral dorsal hippocampi (approximately -1.06 mm / Bregma) that was easily identified in all animals, except one 24-month old APP/PS1 mouse. The area of the internal capsule, lying between the fornix (dorsal) and the medial forebrain bundle (ventral), was manually redrawn from microscopic photographs.

Finally, the midbrain width was measured at -3.4 mm / Bregma [33]. The width of the midbrain was defined as the largest right-left distance of the structure. In all animals, this transverse diameter was perpendicular to the Sylvius aqueduct.

#### 1.4.3. Evaluation of the amyloid load

Amyloid load was quantified on Congo red stained material (see Fig. 1-F) using computer-based thresholding methods. Each stained section was binarized after thresholding in Photoshop. Binarized images were then transferred to Image-Pro Plus software (Media Cybernetics, Silver Spring, USA) and submitted to a particle-detection algorithm to count the

number of plaques and measure their surface on each brain section. The proportion of tissue area occupied by Congo red stained material, which corresponds to the proportion of volume according to Delesse principle [11] was assessed from a total of 13-15 brain slices per animals. This ratio (surface stained / whole section surface) was taken as a global measure of the cerebral “amyloid load” of each individual mice.

Evaluation of the amyloid load was only performed on 24-month old APP/PS1 mice as only a very few congo red positive deposits were observed in young double transgenics.

### **1.5. Statistical analysis and individual studies**

Descriptive statistics were illustrated using means and standard errors to the mean (SEM) of each age/genotype groups' values. Non parametric Mann-Whitney's U tests were used to compare the animal groups (Statistica 6; StatSoft, Inc., Tulsa, USA). Linear correlations were also performed using the Statistica software package.

## **2. Results**

### **2.1. Global brain atrophy**

Brain length assessed by MRI was similar in 10 week old APP/PS1 and PS1 animals (Mann Whitney's  $U=15.5$ , ns). A significant increase of brain length occurred subsequently with aging in APP/PS1 mice ( $U=2$ ,  $p<0.005$ ) but not in PS1 animals ( $U=23$ ; ns). Accordingly brain length was significantly higher in 24-month old APP/PS1 animals than in aged-matched PS1 mice ( $U=2$ ,  $p<0.005$ ).

A positive correlation was obtained between *in vivo* and postmortem measures of global, non corrected, brain volumes ( $r=0.617$ ;  $p<0.001$ ). MRI assessment of brain volume was nevertheless considered to be more accurate than neuropathological evaluation, for four

reasons: 1) extended volume sampling including more anterior and posterior parts of the brain, 2) increased number of serial sections, 3) absence of brain shrinkage usually associated with postmortem studies, 4) opportunity to correct cerebral volume for inter-individual variations of skull sizes. Therefore statistical analysis of global brain volumes presented below were performed using *in vivo* MRI measurements. Histologically-assessed brain volumes were only used to correct for hippocampal volumes measured from brain slices (see below).

At 10 weeks of age, the intracranial volumes and the non-corrected brain volumes were smaller in APP/PS1 than in PS1 animals ( $U_s=3$ ,  $p<0.005$ ; see Fig. 2A). During aging both intracranial and brain volumes increased in APP/PS1 mice ( $U_s<5$ ,  $p<0.005$  and  $p<0.05$  respectively). The same trend was observed in control PS1 animals but did not reach statistical significance ( $U_s>8$ , ns). At 24-months of age APP/PS1 mice still showed reduced brain and intracranial volumes in comparison with PS1 mice but this difference was no longer statistically significant ( $U=15$  and  $14$ , respectively, ns)(Fig. 2A).

In a second step of analysis, MRI brain volumes were corrected for inter-individual variation of the intracranial volume (Fig. 2B) and were similar in young APP/PS1 and PS1 animals ( $U=21$ , ns). Corrected brain volumes were not modified by age in PS1 animals ( $U=9$ , ns) but strongly decreased in old APP/PS1 mice ( $U=0$ ,  $p<0.001$ ). Consequently, 24-month old APP/PS1 mice showed lower corrected brain volumes in comparison to PS1 animals ( $U=3$ ;  $p<.01$ ).

Complementary analysis indicated that the index of global brain atrophy derived from total CSF volume (Fig. 2B) was similar in young APP/PS1 and PS1 animals ( $U=21$ , ns). It was not modified by age in PS1 animals ( $U=10$ , ns) but increased with aging in the APP/PS1 group ( $U=1$ ,  $p<0.005$ ). Accordingly, the index of global brain atrophy was significantly higher in 24-month old APP/PS1 transgenics than in age-matched PS1 animals ( $U=6$ ,  $p<.05$ ).

***Summary: APP/PS1 mice showed smaller brain and cranial volumes at young ages. During aging, these mice nevertheless demonstrated growth of the brain and head (with significant increases in brain length, intracranial volume and brain volume). However a concurrent atrophic process occurred at the same time as indicated by lower corrected brain volumes and an associated increase of CSF volumes in 24-month old APP/PS1 compared with PS1 control mice.***

## **2.2. Brain atrophy related to brain and body weights**

Body and brain weights were similar in young APP/PS1 and PS1 animals ( $U_{s>17}$ , ns; Table 1). Both body and brain weights increased subsequently with aging in PS1 mice ( $U=2$ ,  $p<0.005$  and  $U=8.5$ ,  $p<0.05$ , respectively) but not in APP/PS1 mice ( $U_{s>17}$ , ns). Therefore reduced body and brain weights were observed in 24-month old APP/PS1 animals compared to age-matched PS1 mice (body weights:  $U=3$ ;  $p<.001$ ; brain weights:  $U=0$ ;  $p<.005$ ).

The brain weight / body weight ratio was comparable in young APP/PS1 and PS1 animals ( $U=17$ , ns; Table 1). However, while this ratio significantly decreased with aging in PS1 mice ( $U=2$ ,  $p<0.005$ ), it did not vary in APP/PS1 mice ( $U=23$ , ns). At 24 months of age the brain weight / body weight ratio was consequently lower in PS1 compared to APP/PS1 mice ( $U=4$ ;  $p<.05$ ). Allometric relationship between brain and body weights was noted for PS1 mice ( $r=0.761$ ;  $p<.0025$ ) but not for double transgenics ( $r=0.411$ ; ns). Finally a positive correlation was found between brain weight and brain volume in PS1 mice ( $r=0.641$ ;  $p<.025$ ) but not in APP/PS1 animals ( $r=0.242$ ; ns).

***Summary: PS1 mice showed an expected continuous increase of body and brain weights between 10 weeks and 24 months. The brain/body weight ratio decreased with aging in these animals. APP/PS1 mice did not encompass similar growth. They demonstrated non-proportional growth of brain and body and no relationship between brain volume and weight.***

## **2.3. Measures of regional brain atrophies**

### **2.3.1. Anterior brain areas (Fig. 3A)**

Total CSF volume in the anterior brain and the three indices of regional atrophy in the anterior brain (assessed from CSF volume of the lateral ventricles, 3<sup>rd</sup> ventricle, and periencephalic areas) were similar in young APP/PS1 and PS1 animals ( $U_s > 17$ , ns). Global and regional atrophy indexes were slightly but not significantly increased during aging in PS1 animals. On the contrary, aged APP/PS1, compared to young APP/PS1 mice, displayed a significant increase of global anterior brain atrophy index ( $U=1$ ,  $p < 0.005$ ) and of regional atrophy indexes (3<sup>rd</sup> ventricle:  $U=2$ ,  $p < 0.005$ ; pericortical areas:  $U=4$ ,  $p < 0.01$ ). The differences between CSF indices from the anterior brain were however not significant when aged APP/PS1 were compared to age-matched PS1 mice (all  $U_s > 8$ ; ns).

***Summary: There was an age-related increase of CSF in rostral parts of the brain of APP/PS1 mice. This atrophy remains however of limited importance as direct comparisons between aged PS1 and APP/PS1 mice did not reveal any significant intergroup differences.***

### **2.3.2. Posterior brain areas (Fig. 3B)**

Index of CSF volume in the posterior part of the brain and the four indices of regional atrophy in the posterior brain (CSF volume of the mammillary fossa, areas surrounding the midbrain, and aqueduct of Sylvius) were similar in young APP/PS1 and PS1 animals ( $U_s > 14$ , ns). Comparison of young and aged PS1 animals revealed an age-related significant increase of the midbrain CSF ( $U=3$ ,  $p < 0.005$ ) but not of other indices ( $U_s > 9$ , ns). On the other hand, comparison of young and aged APP/PS1 animals showed severe age-related increase of total posterior atrophy index ( $U=0$ ,  $p < 0.001$ ) as well as regional indices related to the mammillary fossa ( $U=2$ ,  $p < 0.005$ ), midbrain ( $U=0$ ,  $p < 0.001$ ) and aqueduct of Sylvius ( $U=0$ ,  $p < 0.001$ ). The CSF increase in pericortical posterior brain areas of APP/PS1 mice did not reach statistical significance ( $U=13$ , ns). Atrophy of the posterior brain in aged APP/PS1 animals was also

directly demonstrated by significant increases of CSF volumes in these mice compared to age-matched PS1 (posterior part of the brain:  $U= 3$ ,  $p<.01$ ; posterior periencephalic areas:  $U=6$ ,  $p<.05$  ; mammillary fossa:  $U= 5$ ,  $p<.025$ ; areas surrounding the midbrain:  $U=1$ ,  $p<.0025$ ). The only posterior brain region that did not demonstrate signs of atrophy in double transgenic mice was the Sylvius aqueduct area ( $U= 11$ ; ns).

To specify the anatomical origin of the atrophy in the posterior brain, complementary morphological analyses were performed. The surface of the mammillary bodies, evaluated on histological slices, was similar in all the groups ( $U_s > 9$ ; ns). MRI- and histologically-based evaluation of the midbrain height and width were highly correlated ( $r= 0.629$ ,  $p<.0001$ ) and showed no differences between young APP/PS1 and PS1 animals (all  $U_s > 15.5$ , ns). Size of the midbrain did not change significantly with age in APP/PS1 mice ( $U_s > 15$ , ns) but largely increased in PS1 animals ( $U= 0$ ,  $p<0.001$  and  $U=1.5$ ,  $p<0.005$ , respectively for height and width measurements). Consequently, a significant reduction of the midbrain size was noted in aged APP/PS1 compared to aged PS1 animals ( $U=0$ ,  $p<.0025$  for MR evaluation and  $U=0.5$ ,  $p<.0025$  for histological measure)(Fig. 4A).

***Summary: There was a severe age-related increase of CSF in almost all sampled posterior parts of the APP/PS1 brains. In PS1 mice, only the CSF surrounding the midbrain was increased during aging (this was however not related to an atrophy process as direct measurements of the midbrain size did not indicate shrinkage but on the contrary growth of the structure). At 24-months of age, APP/PS1 compared to PS1 mice showed increased CSF volumes in posterior brain areas. The locus of this atrophy in double transgenics was at least partly related to the midbrain region.***

### 2.3.3. Hippocampus (Fig. 5)

The histologically-assessed hippocampal volumes (absolute and corrected by brain volume) were very similar in the two genotypes for animals evaluated at the same age (comparison

between PS1 and APP/PS1 mice, at 10 weeks:  $U=24$ , ns; at 24 months:  $U=10$ , ns). For both genotypes, a significant increase of hippocampal (non-corrected and corrected) volume was found when aged animals were compared to young ones (all  $U_s=0$ ;  $p_s<0.005$  for PS1 animals and  $p_s<0.001$  for APP/PS1 animals). Brain and hippocampal volumes were correlated in young mice, in both genotypes (PS1:  $r=0.819$ ,  $p<0.025$ ; APP/PS1:  $r=0.89$ ,  $p<0.01$ ). At 24-months of age, however, this correlation was only observed in PS1 animals ( $r=0.91$ ,  $p<0.025$ ) but not anymore in APP/PS1 mice ( $r=-0.1$ , ns).

***Summary: Both genotypes showed continuous growth of the hippocampus during adulthood. Hippocampal volumes (absolute or adjusted for inter-individual variations of brain sizes) were not different between PS1 and APP/PS1 animals, whatever the age considered. The fact that brain and hippocampal volumes were not correlated in old APP/PS1 mice nonetheless suggests that all brain structures did not develop and mature equally in these transgenics.***

#### 2.3.4. Fiber tracts

1-The corpus callosum was easily discernable in all animals. No sign of callosal agenesis was detected in any of the 28 studied mice. Rostral and caudal corpus callosum thickness were correlated ( $r=0.378$ ;  $p<0.05$ ) and did not differ in young APP/PS1 and PS1 animals ( $U_s>11$ , ns; see Table 1 and Fig. 4B). During aging, PS1 animals did not display significant variations of callosal size (all  $U_s>10$ ; ns). On the contrary, aged APP/PS1 showed a reduced thickness of the caudal corpus callosum ( $U=1.5$ ,  $p<0.005$ ) in comparison to young APP/PS1 animals (Fig. 4). The rostral thickness of the corpus callosum was not affected in this genotype ( $U=14$ , ns). Atrophy of the corpus callosum was directly confirmed by comparing aged APP/PS1 mice with age-matched PS1 mice (rostral thickness:  $U=3$ ,  $p<0.01$ , and caudal thickness:  $U=5$ ,  $p<0.025$ ). Finally, the corpus callosum length was not different in the four groups of animals ( $U_s>10.5$ , ns).

2-The fornix diameter was similar in young APP/PS1 and PS1 animals ( $U=21.5$ , ns). It decreased with age in APP/PS1 animals ( $U=3.5$ ,  $p<0.005$ ) but not in PS1 mice ( $U=15$ , ns). Therefore, in old mice the fornix diameter was reduced in APP/PS1 animals as compared to PS1 ( $U=0$ ,  $p<0.005$ ; see Fig. 4B and 6).

3-The internal capsule surface was similar in young APP/PS1 and PS1 animals ( $U=25$ , ns). Its size increased with age in PS1 animals ( $U=6$ ,  $p<0.05$ ) but not in APP/PS1 ( $U=16$ , ns). This led to a significant higher surface area of the capsule in aged PS1 animals than in APP/PS1 mice ( $U=1$ ,  $p<0.01$ )(Fig. 4A).

4-The diameter of the mammillothalamic tract did not significantly vary between the two genotypes and between ages (all  $U_s>17$ , ns).

***Summary: lack of normal growth and/or atrophy of the white matter was detected during aging of APP/PS1 mice in different fiber bundles (corpus callosum, fornix, internal capsule). This was not a generalized process as some fiber tracts (eg mammillo-thalamic tract) remained unaffected in this genotype.***

## **2.4. Cerebral A $\beta$ deposition: quantification and correlates**

Amyloid deposition was very extensive in aged APP/PS1 mice (see Fig. 1-F). Congo red stained plaques were mainly observed in iso- and archicortical (hippocampus) brain areas as well as in selected subcortical regions (e.g. thalamus, septal nuclei, amygdala, accumbens nucleus) as previously depicted [3]. PS1 animals did not show any amyloid deposits as expected.

Statistical analyses indicated that the amyloid load of APP/PS1 animals (proportion of surface occupied by Congo red stained material) was not correlated with any of the more than thirty *in vivo* or postmortem variables in brain morphology that we evaluated (including global and regional volumes, with or without correction by intracranial volume, brain weights, and brain structures surface areas, lengths or diameters).

*Summary: no significant relationship was noted between plaque density and the atrophying process.*

### **3. Discussion**

#### **3.1. Cerebral atrophy in APP/PS1 transgenic mice**

The aim of the present study was to assess the impact of cerebral amyloidosis on gross brain morphology in transgenic mice overexpressing Alzheimer-associated mutated genes. We therefore evaluated the occurrence of cerebral atrophy 1) in young adults (10 week-old) transgenic APP/PS1 mice that did not show cerebral A $\beta$  plaques, and 2) in 24 months old APP/PS1 animals demonstrating massive cerebral amyloidosis. Age-matched amyloid deposit-free PS1 animals were used as controls.

*In vivo* MRI and histological methods were chosen because they complemented each other. MRI is well suited for gross anatomical analysis. It prevents morphological distortion related to postmortem tissue processing and allows *in vivo* longitudinal studies. Classically, in histological or MRI studies, atrophy is evaluated by measuring the size of targeted structures of interest. In the present MRI study, atrophy was also estimated by measuring CSF volumes in all brain areas, without a priori identification of the atrophied regions. The MRI contrast was chosen to highlight CSF and not to optimize the contrast between brain structures. Hippocampal volume was therefore evaluated from histology. The contrast and resolution of MRI also did not allow visualization of small structures such as discrete fiber tracts that were consequently measured from histological sections.

At young ages APP/PS1 mice showed reduced brain and intracranial volumes compared with PS1 animals. Then, during adulthood, the double transgenics demonstrated both growth of the brain and of the head. At 24 months of age APP/PS1 mice still maintained a trend towards lower brain and cranial sizes compared with aged-matched control mice, but differences

between genotypes were no longer significant. This suggests that the time window for head-brain development/growth in double transgenics shifts or, at least, is modified compared with normal mice.

Direct analysis of brain and CSF volumes was then performed by correcting MRI volume data by intra-cranial size in order to take into account inter-individual variations in head size. With such ponderated computations, no significant differences were detected between young APP/PS1 and PS1, regardless of the measures considered (total or regional volumes). This indicates that, despite differences in raw volumes, the two studied genotypes showed similar proportional sizes of skull and brain. On the other hand, a significant reduction of brain size and a concomitant increase of CSF volume was found in aged APP/PS1 mice compared with age-matched PS1 as well as young APP/PS1 mice. To our knowledge, this is the first demonstration of global brain atrophy in transgenic mice modeling AD.

Evaluation of the atrophy process by the bias of CSF volumes revealed a discrete atrophy process in the anterior brain of APP/PS1 transgenics. It was only evidenced by an increase in CSF volume during aging that was statistically significant in double transgenics (but not in PS1 mice). Concurrently a robust, although unexpected, dilation of the posterior CSF space was noted in 24-months APP/PS1 animals compared with old PS1 as well as to young APP/PS1 mice. The subsequent step of our investigations was to identify the anatomical loci responsible for the increased CSF volumes in posterior cerebral regions. Reduced volume of the caudal brain was not related to mammillary bodies because, as shown by histology, size of this structure was unaffected by the genotype and did not vary with age. Posterior atrophy was more readily linked to the midbrain region as both MRI and histological analyses revealed a smaller size of the mesencephalic area in aged APP/PS1 than in age-matched PS1 animals.

As a striking result we did not find any evidence of hippocampal atrophy, even in 2 years old APP/PS1 transgenics. These histological findings were indirectly corroborated, from MRI, by

the absence of dilation of the part of the lateral ventricles that surrounds the dorsal hippocampus.

Evaluation of fiber tracts revealed a complex pattern of morphological alterations in APP/PS1 mice : while the mammillo-thalamic tract size was not modified by the genotype, a reduction of the thickness of the corpus callosum, and of the surface of the fornix and internal capsule were detected in aged APP/PS1 compared with PS1 mice.

### **3.2. Brain atrophy vs growth arrest?**

During adulthood and subsequent aging, morphological abnormalities occurring in double transgenics were related to two different processes.

First, our results showed that in control mice some brain structures (midbrain, hippocampus, internal capsule) had continuous growth throughout adulthood. This phenomenon has been addressed and documented in previous studies (e.g. hippocampal growth [34,38]). Similar local brain growth was noted in APP/PS1 animals at the level of the hippocampus. However, other structures (midbrain and the internal capsule) maintained a constant size across age in APP/PS1 mice. This underlines that brain volume reductions noted in aged APP/PS1 transgenics compared to old PS1 mice can readily be due to an interrupted growth of selected cerebral areas rather than to tissue shrinkage arising with aging.

A second process, that could be termed as "classical atrophy", concomitantly occurred in APP/PS1 mice. Hence, for some brain regions (such as the fornix and the caudal corpus callosum), a clear loss of tissue was evidenced during aging in aged double transgenics. This led to reduced brain structure sizes in aged APP/PS1 compared to aged PS1 mice that did not show similar age-related morphological alterations.

Therefore these data suggest that global brain volume reduction and concomitant CSF increase observed in 24-months old APP/PS1 mice is finally due to a dual process, involving

both interruption of continuous (normal) brain growth on one side and tissue loss/shrinkage on the other side.

### ***3.3. Comparison with AD-related brain atrophy and other transgenic mouse models***

**Global brain atrophy** is constantly reported following neuropathological examination of AD patients [51]. A few studies have addressed the question of cerebral atrophy in genetically modified mice modeling AD. To our knowledge all these studies were performed on the PDAPP monogenic model and did not describe significant global brain atrophy [17,38,55]. In our study, when inter-individual differences for skull size were taken into account, a global CSF increase and a concomitant reduction of brain volume could be detected in APP/PS1 animals. A superficial analysis of this point may indicate that the transgenic APP/PS1 model mimics the atrophy associated with AD. However, systematic evaluation of regional CSF volumes suggested that atrophy processes involved mainly posterior brain areas, a pattern very different than that reported in AD. Moreover, our observations indicate that the CSF volume increase in posterior areas is at least partly related to the smaller size of the **midbrain** in aged APP/PS1 compared to PS1 mice. In humans, atrophy of the midbrain is reported during the course of aging [16,27,42,54], but, to the best of our knowledge, is not potentiated in AD patients.

Atrophy of the **hippocampal** formation is a major hallmark of AD [26] and occurs in the earliest stages of the disease [24]. In the PDAPP model of AD, a severe loss of hippocampal volume is also invariably reported, even without precise quantification [14,17,38,55]. It is, however, characterized by a very early and dramatic onset [17,38] which differs strikingly from the progressive hippocampal volume loss noted during the course of AD [21]. It has thus been suggested that hippocampal atrophy in PDAPP mice is related to a neurodevelopmental

abnormality, possibly linked to parenchymal accumulation of soluble A $\beta$ , rather than to a degenerative process [14,38]. Our model did not display developmental related atrophy of the hippocampus because the size of the hippocampus was similar in the two genotypes. Moreover, during adulthood, the hippocampus grew in a similar way in APP/PS1 and in PS1 and the size of the hippocampus that we measured in 24-months APP/PS1 and PS1 animals was comparable to that reported in the literature for aged wild type mice [53]. It can thus not be argued that our control PS1 animals were also atrophied, which would have explained the lack of difference between the two genotypes. It is noticeable that most of the studies on the PDAPP model concerned male animals and not females as in the present study. It is known that hippocampal morphology might be modified by gender [34]. Nevertheless, in our opinion, the sex differences can not explain the lack of hippocampal atrophy in our transgenic model. Furthermore evaluation of the pattern of atrophy in an aged male APP/PS1 animal gave similar results to those obtained in females of the same age/genotype (data not shown). The absence of hippocampal atrophy in our model might concurrently be related to some already-demonstrated protective effect of the PS1 transgene [31] but, in our opinion, could be better explained by variables affecting the phenotype of the different studied models [22]. Such variables can be found at the level of mutated transgenes, promoters or genetic background used to establish the transgenic lines. In any case, the absence of hippocampal atrophy in our APP/PS1 model that, otherwise, displayed very aggressive amyloid pathology suggests that hippocampal tissue loss, as observed in the PDAPP mouse model and in human pathology, is not invariably associated with extracellular A $\beta$  deposition (see next section).

The reduction in size of the internal capsule we have reported in the present study has not been described in either AD patients [5] or transgenic mice models although a recent study has demonstrated morphological abnormalities at the level of the cerebral peduncles in aged PDAPP mice [45], an observation fitting well with our own findings.

Normal development followed by age-related shrinkage of fiber tracts such as the **corpus callosum or the fornix**, was another finding from our study. Corpus callosum [49,50] as well as fornical [8] atrophies are both reported in AD patients. They are also described in PDAPP mice in studies using histological, anatomical MRI or diffusion tensor imaging approaches [17,38,45]. In the PDAPP transgenic model the corpus callosum atrophy is however spectacular, varying from large reduction in size to complete agenesis [14,17,38]. It is far more severe than the atrophy described in our study and in AD pathology [49,50]. Noticeably, in PDAPP mice, the atrophy of the corpus callosum and of the fornix are described at relative young ages (3 months) suggesting that it is also related to some neurodevelopmental disorders. The pattern of atrophy in our model is therefore different because the atrophy was not related to developmental alterations as suggested by similar size in young adult animals. Because the fornix is a major afferent/efferent pathway of the hippocampus and because it is atrophied in PDAPP mice and AD patients that both display hippocampal atrophy, it might be tempting to directly associate atrophy of the fornix with hippocampal volume loss. Nevertheless we reported here fornical atrophy in APP/PS1 mice in the absence of atrophy in the hippocampus or mammillary bodies. This suggests that atrophy of the fornix may be linked to a complex pattern of fiber tract alterations independent of anterograde/retrograde neurodegenerative processes and involves selective brain pathways (e.g. corpus callosum and fornix) but spares others (e.g. mamillo-thalamic tract).

### ***3.4. Cerebral amyloidosis and other neurobiological basis for brain atrophy***

Several observations in humans indicate that the accumulation of neurofibrillary tangles is crucially involved in the atrophy process [4,30]. A somewhat weak correlation between brain atrophy and amyloid load has also been reported in AD and in old mammals developing A $\beta$

deposits [30,48], suggesting that amyloid is an additional causal factor. Evaluation of cerebral atrophy in APP/PS1 mice that develop brain amyloidosis but not NFT is therefore of crucial interest to better describe the relationship between cerebral atrophy and A $\beta$  deposition.

Our study reports the absence of hippocampal atrophy in aged APP/PS1 animals despite heavy amyloid burden. Recent data suggest that intracellular aggregated A $\beta$  is more efficient than parenchymal amyloid plaques to promote hippocampal neuronal loss (and presumably associated local atrophies) [9]. While supporting the hypothesis of a pathogenic role for A $\beta$ , these latter observations strengthen the contention that extracellular plaques do not play a key role per se in macroscopic brain morphological alterations.

Importantly, in the present study, all the (nearly thirty) histological or MRI-based morphological measures taken to quantify global and local atrophies were not correlated with amyloid load. This confirms that extracellular A $\beta$  deposits were not directly involved in the genesis of cerebral atrophy.

The CSF increase in posterior brain regions was (at least partly) related to the reduced size of the midbrain region in APP/PS1 animals. In this area, the plaque density was very low in comparison to isocortical and hippocampal areas. This also underlines the apparent independence of A $\beta$  deposition and onset of localized atrophies.

Our results obtained in mice that did not display tangles, thus support the hypothesis that, in humans, AD-related cortical and hippocampal atrophy is mainly associated with neurofibrillary lesions rather than with A $\beta$  deposition. The corollary is that the lack of NFT lesions in the APP/PS1 animals may explain the different atrophy pattern in these mice compared with AD subjects.

The origin of fiber tract atrophy, in the absence of obvious afferent/efferent brain structure atrophies remains to be elucidated. Because fiber tract alterations are found in different transgenic lines (PDAPP and present APP/PS1 model), one may hypothesize that they are

directly related to the expression of the mutated APP transgene. APP is known to play a key role in neurite outgrowth and axonal guidance during development [37,43] and it has been recently demonstrated that manipulations of APP and APP-like proteins genes, including underexpression and even knocking-out, are accompanied by altered brain development [19] and in particular by dramatic changes at the level of forebrain commissures [28]. Therefore, one can not rule out the possibility that overexpressing (human) APP, especially under mutated forms, leads to detrimental effects during the development of brain connections. Previous studies reported that the degree of fiber tract alteration after modification of the APP gene is also related to animal's genetic background [28]. This may explain the different patterns and intensities of fiber tracts alterations in the PDAPP and APP/PS1 models. The mechanism underlying the origin of fiber tract atrophy might concurrently be explained by 1) a reduced population of existing fibers, such as callosal axons that project from one hemisphere to the other and appear to malfunction in APP transgenics [46]. 2) a reduced number or loss of function of oligodendrocytes responsible for axon myelination. Indeed, recent studies suggest that oligodendrocytes are vulnerable to A $\beta$  toxicity [32]. Deciphering the exact nature of fiber tract atrophies will be the focus of subsequent research efforts.

### **3.5. Concluding remarks**

To summarize, in an APP/PS1 transgenic mouse model, we have provided evidence of slight age-related CSF volume increase in anterior brain areas and of a more severe CSF increase in posterior brain areas. The latter was related to the lack of development of the midbrain during the adulthood period. We also reported alteration of some but not all fiber tracts, that might be related to either interrupted growth or age-related shrinkage in adult APP/PS1. The pathogenic events leading to such morphological alterations however remain to be elucidated. Selected localized brain atrophy in APP/PS1 mice, associated with the absence of severe cortical and hippocampal decline, indicate a pattern of gross anatomical alteration somehow

different than those reported in AD patients. This suggests that overexpression of mutated APP is not invariably accompanied by AD-like brain atrophy. Moreover, we present direct evidence that the severity of atrophy was not reliably correlated with the amyloid load. This challenged the opportunity for using *in vivo* atrophy detection as a surrogate biomarker for microscopic A $\beta$  accumulation. Recent approaches using MRI with targeted contrast agents [35,58] or multiphoton microscopy [25] might be more suitable for addressing such objectives.

## **Acknowledgments**

The Aventis Pharma Alzheimer network is greatly acknowledged for providing transgenic animals used in this study. This study was supported by the CNRS-INSERM joint program 'Small Animal Imaging' (SUB-05/DR12/2002), the INSERM program 'United Thematic Actions on Aging', the Del Duca Foundation, the 'Federation for Brain Research' program, and the 'Neuroscience ACI research' program from the French Minister for Research. We are grateful to Dr S. Davis and J. Horwood for carefully reading and correcting the manuscript.

## References

1. Ashe KH. Learning and memory in transgenic mice modeling Alzheimer's disease. *Learn Mem* 2001; 8(6):301-8.
2. Axel L, Costantini J, Listerud J. Intensity correction in surface-coil MR imaging. *AJR Am J Roentgenol* 1987; 148(2):418-20.
3. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duyckaerts C, Tremp G, Pradier L. Time sequence of maturation of dystrophic neurites associated with Ab deposits in APP/PS1 transgenic mice. *Exp Neurol* 2003; 184(1):247-63.
4. Bobinski M, Wegiel J, Wisniewski HM, Tarnawski M, Reisberg B, De Leon MJ, Miller DC. Neurofibrillary pathology-correlation with hippocampal formation atrophy in Alzheimer disease. *Neurobiol Aging* 1996; 17(6):909-19.
5. Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, Scotti G, Comi G, Filippi M. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. *J Neurol Neurosurg Psychiatry* 2002; 72(6):742-6.
6. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol Aging* 1995; 16(3):271-8; discussion 8-84.

7. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. *Am J Pathol* 2001; 158(3):1173-7.
8. Callen DJ, Black SE, Gao F, Caldwell CB, Szalai JP. Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. *Neurology* 2001; 57(9):1669-74.
9. Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated A $\beta$ 42 accumulation in a novel Alzheimer transgenic model. *Am J Pathol* 2004; 165(4):1289-300.
10. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, Ghzali F, Fallet-Bianco C, Pasquier F, Lebert F, Petit H, Di Menza C. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. *Neurology* 1999; 52(6):1158-65.
11. Delesse MA. Procédé mécanique pour déterminer la composition des roches. *C R Acad Sci* 1847; 25:544-5.
12. Dhenain M, Chenu E, Hisley CK, Aujard F, Volk A. Regional atrophy in the brain of lissencephalic mouse lemur primates: measurement by automatic histogram-based segmentation of MR images. *Magnet Reson Med* 2003; 50:984-92.

13. Dhenain M, Michot JL, Privat N, Picq JL, Boller F, Duyckaerts C, Volk A. MRI description of cerebral atrophy in mouse lemur primates. *Neurobiol Aging* 2000; 21(1):81-8.
14. Dodart JC, Mathis C, Saura J, Bales KR, Paul SM, Ungerer A. Neuroanatomical abnormalities in behaviorally characterized APP(V717F) transgenic mice. *Neurobiol Dis* 2000; 7(2):71-85.
15. Dominguez DI, De Strooper B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. *Trends Pharmacol Sci* 2002; 23(7):324-30.
16. Doraiswamy PM, Na C, Husain MM, Figiel GS, McDonald WM, Ellinwood EH, Jr., Boyko OB, Krishnan KR. Morphometric changes of the human midbrain with normal aging: MR and stereologic findings. *AJNR Am J Neuroradiol* 1992; 13(1):383-6.
17. Gonzalez-Lima F, Berndt JD, Valla JE, Games D, Reiman EM. Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease. *Neuroreport* 2001; 12(11):2375-9.
18. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science* 1992; 256(5054):184-5.
19. Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, Muller U. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. *Embo J* 2004; 23(20):4106-15.

20. Higgins GA, Jacobsen H. Transgenic mouse models of Alzheimer's disease: phenotype and application. *Behav Pharmacol* 2003; 14(5-6):419-38.
21. Jack CR, Jr., Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, Edland SD, Smith GE, Boeve BF, Tangalos EG, Kokmen E, Petersen RC. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. *Neurology* 2002; 58(5):750-7.
22. Janus C, Westaway D. Transgenic mouse models of Alzheimer's disease. *Physiol Behav* 2001; 73(5):873-86.
23. Jellinger KA, Bancher C. Neuropathology of Alzheimer's disease: a critical update. *J Neural Transm Suppl* 1998; 54:77-95.
24. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. *Ann Neurol* 2000; 47(4):430-9.
25. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. *J Neuropathol Exp Neurol* 2002; 61(9):797-805.

26. Lehericy S, Baulac M, Chiras J, Pierot L, Martin N, Pillon B, Deweer B, Dubois B, Marsault C. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. *Ajnr: American Journal of Neuroradiology* 1994; 15(5):929-37.
27. Luft AR, Skalej M, Welte D, Kolb R, Klose U. Reliability and exactness of MRI-based volumetry: a phantom study. *J Magn Reson Imaging* 1996; 6(4):700-4.
28. Magara F, Muller U, Li ZW, Lipp HP, Weissmann C, Stagljar M, Wolfer DP. Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the beta-amyloid-precursor protein. *Proc Natl Acad Sci U S A* 1999; 96(8):4656-61.
29. Nagy Z, Hindley NJ, Braak H, Braak E, Yilmazer-Hanke DM, Schultz C, Barnettson L, King EM, Jobst KA, Smith AD. The progression of Alzheimer's disease from limbic regions to the neocortex: clinical, radiological and pathological relationships. *Dement Geriatr Cogn Disord* 1999; 10(2):115-20.
30. Nagy Z, Jobst KA, Esiri MM, Morris JH, King EM, MacDonald B, Litchfield S, Barnettson L, Smith AD. Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. *Dementia* 1996; 7(2):76-81.
31. Nakajima M, Miura M, Aosaki T, Shirasawa T. Deficiency of presenilin-1 increases calcium-dependent vulnerability of neurons to oxidative stress in vitro. *J Neurochem* 2001; 78(4):807-14.

32. Pak K, Chan SL, Mattson MP. Presenilin-1 mutation sensitizes oligodendrocytes to glutamate and amyloid toxicities, and exacerbates white matter damage and memory impairment in mice. *Neuromol Med* 2003; 3(1):53-64.
33. Paxinos G, Franklin KBJ. *The mouse brain in stereotaxic coordinates*. (second ed.) San Diego: Academic Press, 2001:
34. Peirce JL, Chesler EJ, Williams RW, Lu L. Genetic architecture of the mouse hippocampus: identification of gene loci with selective regional effects. *Genes Brain Behav* 2003; 2(4):238-52.
35. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ, Jack CR, Jr. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. *Neurobiol Dis* 2002; 11(2):315-29.
36. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. *J Histochem Cytochem* 1962; 10:355-64.
37. Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ. Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. *J Neurosci* 1995; 15(3 Pt 2):2157-67.
38. Redwine JM, Kosofsky B, Jacobs RE, Games D, Reilly JF, Morrison JH, Young WG, Bloom FE. Dentate gyrus volume is reduced before onset of plaque formation in PDAPP

mice: a magnetic resonance microscopy and stereologic analysis. *Proc Natl Acad Sci U S A* 2003; 100(3):1381-6.

39. Rosen GD, Harry JD. Brain volume estimation from serial section measurements: a comparison of methodologies. *J Neurosci Methods* 1990; 35(2):115-24.

40. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper MA, Steinling M, Wolters EC, Valk J. Atrophy of the medial temporal lobes on MRI in Alzheimer's disease and normal aging. Diagnostic value and neuropsychological correlates. *J Neurol Neurosurg Psychiatry* 1992; 55(10):967-72.

41. Schmitz C, Rutten BP, Pielen A, Schafer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch HW, Pradier L, Bayer TA. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. *Am J Pathol* 2004; 164(4):1495-502.

42. Shah SA, Doraiswamy PM, Husain MM, Figiel GS, Boyko OB, McDonald WM, Ellinwood EH, Jr., Krishnan KR. Assessment of posterior fossa structures with midsagittal MRI: the effects of age. *Neurobiol Aging* 1991; 12(4):371-4.

43. Small DH, Clarris HL, Williamson TG, Reed G, Key B, Mok SS, Beyreuther K, Masters CL, Nurcombe V. Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease. *J Alzheimers Dis* 1999; 1(4-5):275-85.

44. Sommer B. Alzheimer's disease and the amyloid cascade hypothesis: ten years on. *Curr Opin Pharmacol* 2002; 2(1):87-92.
45. Song SK, Kim JH, Lin SJ, Brendza RP, Holtzman DM. Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition. *Neurobiol Dis* 2004; 15(3):640-7.
46. Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. *J Neurosci* 2004; 24(19):4535-40.
47. Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T. Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. *Am J Pathol* 2000; 157(1):331-9.
48. Tapp PD, Siwak CT, Gao FQ, Chiou JY, Black SE, Head E, Muggenburg BA, Cotman CW, Milgram NW, Su MY. Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. *J Neurosci* 2004; 24(38):8205-13.
49. Teipel SJ, Bayer W, Alexander GE, Zebuhr Y, Teichberg D, Kulic L, Schapiro MB, Moller HJ, Rapoport SI, Hampel H. Progression of corpus callosum atrophy in Alzheimer disease. *Arch Neurol* 2002; 59(2):243-8.

50. Teipel SJ, Hampel H, Pietrini P, Alexander GE, Horwitz B, Daley E, Moller HJ, Schapiro MB, Rapoport SI. Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease. *Arch Neurol* 1999; 56(4):467-73.
51. Valk J, Barkhof F, Scheltens P. *Magnetic Resonance in Dementia*. Heidelberg Berlin New York: Springer-Verlag, 2002.
52. van Leuven F. Single and multiple transgenic mice as models for Alzheimer's disease. *Prog Neurobiol* 2000; 61(3):305-12.
53. Von Bohlen und Halbach O, Unsicker K. Morphological alterations in the amygdala and hippocampus of mice during ageing. *Eur J Neurosci* 2002; 16(12):2434-40.
54. Weis S, Kimbacher M, Wenger E, Neuhold A. Morphometric analysis of the corpus callosum using MR: correlation of measurements with aging in healthy individuals. *AJNR Am J Neuroradiol* 1993; 14(3):637-45.
55. Weiss C, Venkatasubramanian PN, Aguado AS, Power JM, Tom BC, Li L, Chen KS, Disterhoft JF, Wyrwicz AM. Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP V717F mice. *Neurobiol Dis* 2002; 11(3):425-33.
56. Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA. Intraneuronal Abeta accumulation precedes plaque formation in

beta-amyloid precursor protein and presenilin-1 double-transgenic mice. *Neurosci Lett* 2001; 306(1-2):116-20.

57. Wirths O, Multhaup G, Czech C, Blanchard V, Tremp G, Pradier L, Beyreuther K, Bayer TA. Reelin in plaques of beta-amyloid precursor protein and presenilin-1 double-transgenic mice. *Neurosci Lett* 2001; 316(3):145-8.

58. Zaim Wadghiri Y, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguilnaldo G, Pappolla M, Duff K, Wisniewski TM, Turnbull DH. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. *Magnet Reson Med* 2003; 50:293-302.

## Table and Figure legends

### Table 1.

Mean  $\pm$  standard error of the mean of morphometric measures taken from APP/PS1 and PS1 animals. Significant differences between the two genotypes are highlighted.  $\nearrow$ : Significant increase / decrease between young and old mice of the same genotype (AGING effect);  $\star$ : Significant difference between PS1 and APP/PS1 mice at one particular age (GENOTYPE effect)

<sup>1</sup> Histologically assessed hippocampal volumes were corrected by brain volumes also derived from postmortem brain sections.

**Figure 1.** MRI (A, B, C) and Congo red stained (D, E, F) coronal sections, at the level of the dorsal hippocampus, of APP/PS1 (B, C, E, F) and PS1 (A, D) animals. MRI sagittal view of the brain of an APP/PS1 animal is illustrated in panel G.

On MR sections CSF regions are labeled as follows: Green: CSF<sub>LV</sub> ; Blue: CSF<sub>3V</sub> ; Red: CSF<sub>antC</sub> ; Purple: CSF<sub>mam</sub> ; Pale green: CSF<sub>midbrain</sub> ; Yellow: CSF<sub>sylv</sub>. The large green line in G represents the distance used to measure the height of the midbrain on MRI images; the thin green lines were taken as landmarks to evaluate this height between the basis of the aqueduct of Sylvius and the roof of the mammillary fossa.

Note the high density of plaques in the aged APP/PS1 mouse (F) and the absence of amyloid A $\beta$  deposition in the young mice of the same genotype (E) and in PS1 control animal (D).

### Figure 2.

A: Comparison of intracranial and whole brain volumes measured by *in vivo* MRI in 10 weeks old (Y) and 24 months old (O) APP/PS1 and PS1 mice (mean  $\pm$  SEM). B: Brain and

CSF volume indices (i.e. after correction for individual differences in intracranial volume - IC). ☆: Age-related significant differences between animals of the same genotype; \*: Significant differences between age-matched APP/PS1 and PS1 animals.

### Figure 3.

Regional CSF volumes in young (Y) and old (O) PS1 and APP/PS1 genotypes (mean  $\pm$  SEM). A: anterior periencephalic areas (CSF<sub>antC</sub>), third ventricle and part of the lateral ventricle anterior to the interventricular foramen (CSF<sub>3V</sub>), part of the lateral ventricles posterior to the interventricular foramen (CSF<sub>LV</sub>). B: posterior peri-encephalic areas (CSF<sub>postC</sub>), regions surrounding the midbrain (CSF<sub>midbrain</sub>), mammillary fossa (CSF<sub>mam</sub>), and aqueduct of Sylvius (CSF<sub>sylv</sub>). ☆: Age-related significant differences between animals of the same genotype; \*: Significant differences between age-matched APP/PS1 and PS1 animals.

### Figure 4.

Evaluation of the size of various brain structures in 10 weeks old (Y) and 24 months old (O) APP/PS1 and PS1 mice (mean  $\pm$  SEM). A: midbrain and internal capsule showed growth arrest in APP/PS1 transgenics; B: caudal part of the corpus callosum and fornix demonstrated shrinkage during aging in APP/PS1 mice. ☆: Age-related significant differences between animals of the same genotype; \*: Significant differences between age-matched APP/PS1 and PS1 animals.

### Figure 5.

Hippocampal gross morphology in 24 months old APP/PS1 (A) and PS1 (B) mice. The graph (C) shows the size of the hippocampus in young (Y) and old (O) mice. Hippocampal growth occurred in both genotypes. Despite severe plaque-induced alterations of cytoarchitecture

(arrow heads in A), the hippocampus of aged APP/PS1 mice was not significantly atrophied compared with PS1 control animals. ☆: Age-related significant differences between animals of the same genotype.


**Figure 6.**

Morphological analysis revealed a reduction in fornical cross-sectional diameter in old double APP/PS1 transgenics (A) compared with age-matched PS1 mice (B). Insets in upper corners represent high magnification of the area bordered with dotted lines in the background photographs. Arrow heads set the limits of the fornix diameter. Scale bar, for both insets: 300  $\mu\text{m}$ . Annotations: PV: paraventricular hypothalamic nucleus; 3V: third ventricle.


	YOUNG		OLD	
	PS1	APP/PS1	PS1	APP/PS1
Body weight (g)	20.3 ± 0.6	19.1 ± 0.5	31.4 ± 3.5 ↗	19.2 ± 1.3
Brain weight (mg)	495 ± 5	487 ± 6	520 ± 8 ↗	475 ± 9
Brain weight / body weight (%)	2.45 ± 0.06	2.55 ± 0.04	1.76 ± 0.16 ↘	2.52 ± 0.15
Brain length (mm)	9.0 ± 0.1	8.8 ± 0.1	9.0 ± 0.1	9.4 ± 0.1 ↗
Hippocampus vol. / brain vol. (%) <sup>1</sup>	7.8 ± 0.1	7.7 ± 0.2	9.4 ± 0.1 ↗	9.4 ± 0.3 ↗
Mammillary bodies surface (mm <sup>2</sup> )	2.2 ± 0.2	2.3 ± 0.2	2.6 ± 0.2	2.1 ± 0.2
Midbrain height (mm)	2.64 ± 0.02	2.59 ± 0.03	2.83 ± 0.04 ↗	2.55 ± 0.03
Rostral corpus callosum thickness (mm)	0.44 ± 0.02	0.39 ± 0.02	0.49 ± 0.03	0.33 ± 0.03
Corpus callosum length (mm)	3.5 ± 0.2	3.4 ± 0.1	3.7 ± 0.1	3.5 ± 0.1
Mammillo-thalamic tract diameter (mm)	0.27 ± 0.02	0.26 ± 0.01	0.26 ± 0.01	0.26 ± 0.01

Table 1

PS1 old



APP/PS1 young



APP/PS1 old







Figure 1




Figure 2




Figure 3




Figure 4




Figure 5





Figure 6